WOODCLIFF LAKE, N.J., March 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that Paul V. Campanelli has been named president, Generics Division. In this capacity, Mr. Campanelli will head the fifth largest U.S. generic pharmaceutical company and continue to oversee the Business Development and Licensing group he formed when he joined Par in 2001. He has also been elected a corporate officer by the company’s board of directors.
“We are fortunate to have a leader like Paul, whose energy, industry knowledge and management expertise I’m confident will continue to help grow this important business,” said Patrick G. LePore, president and chief executive officer. “The quality of Par’s generic pipeline reflects Paul’s hard work and understanding of a complex industry, as well as the substantial number of productive relationships with business partners he has managed to cultivate.”
Mr. Campanelli has executed more than 60 agreements and in-licensed more than 100 products with 30 companies since coming to Par. He most recently served as executive vice president, Business Development and Licensing, and has held a series of increasingly responsible positions since joining Par as senior director, Business Development. He was vice president, business development, at Dr. Reddy’s Laboratories, Inc., where he worked from 1997- 2001, and held sales and marketing positions of increasing responsibility at Reddy-Cheminor, Inc., where he worked from 1991-97.
About Par
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.
Par Pharmaceutical Companies, Inc.
CONTACT: Investor, Stephen J. Mock; Media, Peter Wolf, Par PharmaceuticalCompanies, Inc., +1-201-802-4000
Web site: http://www.parpharm.com/
